Kornimate/medical-research-clean huggingface dataset:
multiplex laser vs. pdl (pulsed dye laser ) in the treatment of surgical scars

Conditions: Scar

Summary: this study aims to determine if the 595nm pulsed dye laser, the combined 595/1064nm multiplex laser or no treatment results in a better outcome in the quality of the surgical scar using the multiplex cynergy laser, starting treatment the day of suture removal.

this study aims to determine if the 595nm pulsed dye laser, the combined 595/1064nm multiplex laser or no treatment results in a better outcome in the quality of the surgical scar using the multiplex cynergy laser, starting treatment the day of suture removal. patients will be offered the opportunity of enrolling in the trial before their surgery. if they qualify and agree to participate they will sign informed consent and health insurance portability and accountability act (hipaa) form. the surgical defect should be closed primarily, with the minimal scar length being 3cm. the scar will be randomized into 3 equal thirds, each third will randomly receive either: no treatment, 595nm pdl, or 595/1064nm multiplex laser. a total of 3 laser treatments will be performed over a period of 3 weeks (one treatment session performed every week), and the patient will come in for a final follow up visit, for a final assessment of the scar using the patient and observer scar assessment scale (posas) system.

Eligibility criteria:
inclusion criteria: * fitzpatrick skin types 1-3 * suture line should be at least 3 cm long exclusion criteria: * the patient should not be receiving any alternate systemic, topical or intralesional treatment of the scars during the study * pregnant or lactating females * fitzpatrick skin type 4-6 * a history of keloids or hypertrophic scars
a comparative trial of tms approaches to treating depression

Conditions: Depression

Summary: trancranial magnetic stimulation (tms) is a non-drug and non-invasive treatment for depression and has been investigated for the treatment of psychiatric illness for over 15 years. there is now established evidence indicating tms is an effective treatment for depression. however, the effectiveness of tms varies between people, thus requiring further research to investigate its optimal application. investigators want to compare the effectiveness of different forms of tms, given with differing stimulation settings to the right or left side of the brain that has been associated with depression. this could potentially help clinicians in the future to improve the prescription of tms as a treatment for depression.


Eligibility criteria:
inclusion criteria: 1. age ≥18 years. 2. dsm-iv diagnosis of current major depressive episode. 3. madrs score of 20 or more. 4. able to give informed consent. exclusion criteria: 1. dsm-iv psychotic disorder. 2. drug or alcohol abuse or dependence (preceding 3 months). 3. inadequate response to ect (current episode of depression). 4. rapid clinical response required, e.g. high suicide risk. 5. significant neurological disorder, which may pose increased risks with tms, e.g., epilepsy. 6. metal in the cranium, skull defects, pacemaker, cochlear implant, medication pump or other electronic device. 7. pregnancy.
changes in vessels after peripheral block

Conditions: Anesthesia, Local; Vena Cava Syndrome (Inferior) (Superior); Fluid Loss; Postoperative Pain

Summary: in patients with fluid deficit, vasoconstriction occurs in peripheral tissues and blood circulation is kept in the central area. it causes arterial vasodilation and hemodynamic variability by increasing the blood volume of the extremity due to the sympathectomy occurring after the block. when the investigators classify patients according to vci-ci, it will be questioned whether there is a difference between patients' block quality and hemodynamic variability.

vci-ci helps us to have an idea about the amount of fluid in patients according to the vena cava inferior (vci) diameter and the diameter between the inspiring and expiration. low arterial diameter and high inspiratory and expiratory variability indicate that the patient's fluid volume may be lower. in the measurement of vci diameter, vci has visualized in the craniocaudal plane thanks to the transverse ultrasound probe. changes in vci diameter are observed depending on the negative pressure in the thoracic area during inspiration and expiration. when the difference between this rate of change is greater than 50%, it indicates that the patient has a fluid deficit. the fact that the vci diameter is also below 1.5 cm indicates that this amount of fluid requirement is more serious. in this study, the investigators will question whether there is a difference between patients' block quality and hemodynamic variability when they classify patients according to vci-ci.

Eligibility criteria:
inclusion criteria: * hand and wrist elective surgery * infraclavicular block will be applied * american society of anesthesiologists (asa) physical condition i-ii * patients aged 18-65 years exclusion criteria: * contraindication for central or peripheral blocks * cognitive dysfunction * history of chronic opioid use * severe organ dysfunction * allergy to any drug used in the study * body mass index (bmi) ≥30 * infection in the area to be treated * refusal to participate in the research

Keywords: vena cava inferior collapsibility index lateral sagittal infraclavicular block vci-ci
surgical safety and effectiveness in orthopedics: swiss-wide multicenter evaluation and prediction of core outcomes in arthroscopic rotator cuff reconstruction

Conditions: Rotator Cuff Tear

Summary: surgical safety and effectiveness in orthopedics: swiss-wide multicenter evaluation and prediction of core outcomes in arthroscopic rotator cuff reconstruction.

in this project prospective data are collected from a representative group of specialized clinics performing arthroscopic rotator cuff repair (arcr) to serve as reference baseline and outcome values, as well as the development of prediction models for individual patients. ultrasound and mri (on a subset of patients) examination will be performed at 12 months.

Eligibility criteria:
inclusion criteria: * adult patients * diagnosed with a partial or full-thickness rotator cuff tear using magnetic resonance imaging (mri) * planned primarily surgical partial or complete repair by arthroscopic procedure * able to understand the content of the patient information/ consent form and give consent to take part in the project exclusion criteria: * surgical procedure for irreparable tears, i.e. muscle transfer, acromio-humeral spacer or superior capsular reconstruction * revision surgery (prior repair of the rotator cuff in the same shoulder) * planned open or mini-open reconstructions * patients with a language barrier hindering questionnaire completion (either in german, french, italian or english) * patients unlikely to attend clinical follow-up * pregnancy * legal incompetence

Keywords: oxford shoulder score (oss) shoulder stiffness arthroscopic rotator cuff repair
registry of hospitalized patients treated with fondaparinux

Conditions: Deep Vein Thrombosis; Pulmonary Embolism

Summary: registry of hospitalized patients at brigham and women's hospital treated with fondaparinux

the use of antithrombotic agents in the hospital is the mainstay of therapy for the treatment or prophylaxis of venous thromboembolism (vte) and acute coronary syndrome (acs). concern with the administration of heparins and risk for adverse sequelae has led to the development of newer, longer-acting agents. fondaparinux offers once daily administration with only an extremely small risk of developing heparin induced thrombocytopenia. recent data have further demonstrated the efficacy and safety of fondaparinux in vte and acs, expanding its use in clinical practice. we aim to: 1) determine how fondaparinux is being used in a "real life" clinical setting, a tertiary-care academic medical center (bwh), and 2) assess the associated clinical outcomes at 90 days after initiation of fondaparinux.

Eligibility criteria:
inclusion criteria: * bwh hospitalized patients receiving fondaparinux

Keywords: anticoagulation thrombosis bleeding clotting pulmonary embolism deep vein thrombosis
analysis of the causes of redo pull-through for recurrent constipation and the risk factors affecting the prognosis of the hirschsprung's disease and allied disorders

Conditions: Surgery; Pediatric ALL

Summary: the goal of this observational study is to conducted a comprehensive analysis of the factors contributing to redo- pull-through surgery for constipation recurrence in children who are suffering from hirschsprun' s disease (hscr) and its allied disorders (adhd) . the main question\[s\] it aims to answer are: 1. our study focused on the treatment and prognosis of these conditions, drawing upon 16 years of patient data and clinical experiences" 2. what are the key risk factors affecting the prognosis of recurrent constipation patients undergoing repeat pt?


Eligibility criteria:
inclusion criteria: 1. patients admitted to the department of pediatric surgery at tongji hospital, tongji medical college, huazhong university of science and technology, between january 2005 and december 2021; 2. hscr and adhd patients admitted due to "constipation recurrence" and requiring redo-pt. exclusion criteria: 1. patients undergoing staged surgeries or undergoing internal sphincterotomy; 2. patients with concomitant severe congenital anomalies such as down syndrome; (3) patients with incomplete postoperative follow-up data after redo-pt.
the effects of focal vibration on spasticity in multiple sclerosis patients

Conditions: Multiple Sclerosis

Summary: this trial consists of application of little devices (named equistasi®) generating focal vibrations to treat spasticity in neurological patients, affected by multiple sclerosis. the expected effects are on gait and postural instability.


Eligibility criteria:
inclusion criteria: * multiple sclerosis affected * spasticity * edss (expanded disability status scale) 0 - 5,5 * patients able to sign informed consent exclusion criteria: * age less than 18 years old and more than 65 years old * pacemaker * pregnancy * comorbidities as: cancer, hypertension not controlled by drugs * concurrent therapies with antidepressant or corticosteroids

Keywords: focal vibrations neurorehabilitation spasticity multiple sclerosis
pd-l1 specific 68ga-thp-pd-l1-3 probe for pet imaging in solid tumors

Conditions: Solid Tumor

Summary: the objective of the study is to constrcut a noninvasive approach 68ga-thp-pd-l1-3 pet/ct to detect the pd-l1 expression of tumor lesions in patients with solid tumors and to identify patients benefiting from anti-pd-l1 treatment.

analysis plan: 1. recruit 10 participants to analyze preliminary pharmacokinetic/first-in-human dose (fih), major organ distribution and tumor uptake information via whole-body pet/ct imaging; 2. recruit 20-30 participants to analyze in vivo safety and tumor targeting information; and 3. recruit all participants for a final summary.

Eligibility criteria:
inclusion criteria: 1. aged \>18 years old; ecog 0 or 1; 2. patients with solid tumorsin or suspected tumor lesions; 3. life expectancy \>=12 weeks. exclusion criteria: 1. significant hepatic or renal dysfunction; 2. is pregnant or ready to pregnant; 3. cannot keep their states for half an hour; 4. refusal to join the clinical study; 5. suffering from claustrophobia or other mental diseases; 6. any other situation that researchers think it is not suitable to participate in the experiment
study of tamibarotene in patients with adpkd

Conditions: Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Summary: clinical trial of tamibarotene in patients with autosomal dominant polycystic kidney disease


Eligibility criteria:
inclusion criteria: * patients diagnosed as adpkd by modified pei-ravine * egfr(ckd-epi) is equal to or greater than 60 ml/min/1.73m\^2 * patients who are judged to be hard to treat with tolvaptan or who do not wish to be treated with tolvaptan, at the time of obtaining consent * patients with systolic blood pressure below 140 mmhg and diastolic blood pressure below 90 mmhg. for patients receiving angiotensin-converting enzyme inhibitors or angiotensin ii receptor antagonists, the dose must be constant for at least 6 weeks before obtaining informed consent exclusion criteria: * women who are pregnant or may be pregnant * nursing mother * females with childbearing potential or male subjects with a fertile partner who is unable to use contraception for the following periods: 1. female: from informed consent to 2 years after the last administration of the study drug 2. male: from informed consent to 6 months after the last administration of the study drug * patients within 12 weeks from the last dose of a drug that affects renal cysts, such as tolvaptan, to the first dose of the study drug * patients with complications of intracranial aneurysm, malignant tumor, uncontrolled diabetes, osteoporosis, uncontrolled dyslipidemia, or abnormal liver function

Keywords: autosomal dominant polycystic kidney disease
adherence and outcome of upper airway stimulation (uas) for osa international registry

Conditions: Obstructive Sleep Apnea

Summary: inspire intends to conduct this registry to: 1) collect inspire therapy clinical evidence in the clinical practice setting; 2) collect additional information on the effectiveness, use and safety in the commercial setting; and 3) engage physician customers to report the collective outcome within a group of properly trained programs that utilize inspire therapy on a regular basis. in addition, a sub-study will be conducted under this registry at a limited number of registry centers and will include a cohort of registry patients and a cohort of patients who have not received the inspire therapy device due to denial of insurance coverage. the two sub-study cohorts' quality of life and ahi data will be compared.

this registry is a multi-center, prospective, observational registry, conducted in the united states and europe. some data may be collected retrospectively in patients currently implanted (implanted prior to enrollment) through the 12-month follow-up time frame. the ce-marked and fda-approved inspire system will be used within its intended use, allowing for of use of any future approved system component models. this protocol does not include any additional stressful or invasive tests, which are not a part of standard of care.

Eligibility criteria:
inclusion criteria: any patient implanted with or receiving an inspire implant, who meets the following criteria, is eligible to participate in the registry: 1. capable of giving informed consent, as required per institution 2. willing to return for routine clinic visits as required for inspire therapy management exclusion criteria: any patient who meets any of the following criteria will not be eligible to participate in the registry 1. has a life expectancy of less than 1 year 2. any reason the clinician deems patient is unfit for participation in the study

Keywords: neurostimulation hypoglossal nerve tongue upper airway stimulation surgery
arthroscopic assisted cc stabilization alone vs additional k-wire fixation for acute acromioclavicular joint injury

Conditions: Acromioclavicular Joint Dislocation

Summary: this rct study is designed for comparing functional outcomes and radioligic outcomes between intervention group (arthroscopic assisted cc-stabilzation with additional k-wire fixation) and control group (arthroscopic assisted cc-stabilzation alone) for acute acji. the main question it aims to answer is: - does arthroscopic assisted cc-stabilization with additional k-wire fixation provide different outcomes in functional outcomes, cc-distance and gaca difference compare with arthroscopic assisted cc-stabilization alone in acute acromioclavicular joint injury?

acromioclavicular joint injury (acji) is one of the most common injury of shoulder joint. most common mechanism of injury is from direct force apply to the affected shoulder, in adduction position, in acromion process area. most of the intervention that have been used for treat acji are focused on pain control, maintain the strength of the joint, no limitation in daily life activity and full range of motion of affected shoulder. operative treatment is indicated in acji rockwood classification grade iii, iv, v, and vi. nowadays there are over 60 surgical techniques without gold standard. arthroscopic assisted cc-stabilzation is one of the most popular technique that has been used for acji. this rct study is designed for comparing functional outcomes (acji score, vas, constant score and dash score) and radioligic outcomes (cc-distance difference, gaca difference) between intervention group (arthroscopic assisted cc-stabilzation with additional k-wire fixation) and control group (arthroscopic assisted cc-stabilzation alone) for acute acji. the main question it aims to answer is: - does arthroscopic assisted cc-stabilization with additional k-wire fixation provide different outcomes in functional outcomes, cc-distance and gaca difference compare with arthroscopic assisted cc-stabilization alone in acute acromioclavicular joint injury?

Eligibility criteria:
inclusion criteria: * age 18-45 years old * acute ac joint injury rockwood classification iii, iv and v exclusion criteria: * history of underwent previous ipsilateral shoulder surgery * specific active associated ipsilateral injury (rib fractures, clavicel fractures, scapula fractures and base of coracoid fractures) * onset of injury more than 3 weeks * cannot underwent arthroscopic assisted cc-stabilization surgery

Keywords: arthroscopic assisted cc-stabilization ac joint injury
developing advanced blood-brain barrier permeability imaging for early ad

Conditions: Alzheimer Disease

Summary: aging is the primary risk factor in aging-related dementia. an important initiating factor for the development and progression of cognitive impairment is disruption of the blood-brain barrier (bbb). bbb plays an important role in maintaining normal brain homeostasis and protecting neural tissues from toxins. it is hypothesized that such changes known to be common in aging and can be an early process that precedes alzheimer's disease (ad). the microvascular changes related to subtle bbb disruption can be measured with permeability-surface area (ps) derived from grasp dce-mri acquired less than 10 minutes, and the patterns of increased ps in normal and abnormal aging are different.


Eligibility criteria:
inclusion criteria: * subjects that have been diagnosed with amci ages 65-85 exclusion criteria: * pregnant, planning to get pregnant, or nursing. * claustrophobia * cardiac pacemaker * intracranial clips, metal implants, unremovable jewelries, metal in eyes. * history or presence of any other major medical, neurologic or psychiatric conditions, such as alzheimer's diseases, parkinson's diseases, and stroke. * renal or liver disease as this may cause concerns related to gad-based contrast agent * allergy to the contrast agent gadolinium
suicide sleep monitoring (ssleem)

Conditions: Suicide, Attempted

Summary: promising results have shown that interventions to reduce insomnia diminish suicidal ideation. a better understanding of the bidirectional mechanism between sleep disturbances and suicide behavior will allow the design of tailored interventions to prevent suicide attempts. significance of the proposed study for the field the aim of the present is to assess the feasibility and the acceptability of sleep tracking monitoring in a sample of suicide attempters. the investigator hypothesize that sleep monitoring using a connected object is feasable and acceptable by patients.


Eligibility criteria:
inclusion criteria: * male or female, aged 18 or older, * with suicide attempt or suicidal ideas history, * able to understand the study, * insured persons, * having signed a consent form. exclusion criteria: * minor patient, * patient whose clinical status is incompatible with informed consent, * patient tattooed on both wrists * patient under guardianship or curatorship
clinical trial comparing tranexamic acid (txa) with aquamantys sealer in total knee arthroplasty (tka)

Conditions: Blood Loss

Summary: the aim of the study is to determine if the use of iv txa or aquamantys system improve the postoperative hemoglobin and hematocrit after primary tka and what is the effect of the simultaneous use of iv txa and aquamantys on the postoperative hemoglobin and hematocrit. the assumption is that the combination of iv txa and aquamantys system will enable an improvement in the postoperative hemoglobin and hematocrit equal or larger than the improvement generated by the use of aquamantys system alone.

the study is randomized, placebo controlled. the study population includes patients older than 18 years of age undergoing elective total primary knee replacement under spinal anesthesia. all patients enrolled in the study will undergo tka performed by the same orthopedic surgeon. since controversies exist regarding the effect of different types of anesthesia (general anesthesia versus spinal or epidural anesthesia) on intraoperative blood loss, in order to eliminate an important confounding variable we decided to exclusively enroll for our study patients that qualify for and agree with spinal anesthesia to be used as the main anesthetic technique for their tka. all clinical trial procedures will be performed by personnel blinded to study treatment assignment. unblinding is only allowed for safety concerns in an emergency situation.the only other exception is represented by the surgeon, who can't be blinded in regards to using aquamantys system and the bipolar sealer. once a subject becomes eligible for the trial, the investigator or the designee will access the randomization system. enrolled subjects will be assigned to one of the 4 groups by block randomization of alternating 4 and 8 and 12 patients per block. the pharmacy department will provide the iv placebo or the iv txa according to the randomization process. this clinical trial will be conducted in accordance to this protocol, good clinical practice and applicable regulatory requirements

Eligibility criteria:
inclusion criteria: * adult patients over age of 18 undergoing elective total primary knee arthroplasty under spinal anesthesia. exclusion criteria: * previous adverse reaction to tranexamic acid * congenital or acquired coagulation disorders * preoperative platelet count of less than 100,000/microliter or inr\> 1.4 * history of deep venous thrombosis, pulmonary embolism or cerebrovascular accident * patients with acquired defective color vision * renal insufficiency (glomerular filtration rate \<20 ml/min) * severe liver disease * coronary stents * pregnant patients * main anesthetic other than spinal anesthesia

Keywords: tranexamic acid blood loss aquamantys system tka